Potential pitfalls of crossover and thoughts on iniparib in triple-negative breast cancer

Journal of the National Cancer Institute

Volumn 103, Issue 23, 2011, Pages 1738-1740

  Fojo, Tito ^a   Amiri Kordestani, Laleh ^a   Bates, Susan E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BRCA1 PROTEIN; BRCA2 PROTEIN; CARBOPLATIN; GEMCITABINE; INIPARIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PLACEBO; SUNITINIB;

CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL (TOPIC); CROSSOVER PROCEDURE; DISEASE COURSE; GENE MUTATION; KIDNEY CARCINOMA; METASTASIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; TRIPLE NEGATIVE BREAST CANCER;

ANTINEOPLASTIC AGENTS; BENZAMIDES; BREAST NEOPLASMS; CONFOUNDING FACTORS (EPIDEMIOLOGY); CROSS-OVER STUDIES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INDOLES; INTERFERON-GAMMA; NEOPLASMS; PATIENT SELECTION; PYRROLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 83255173944     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr386     Document Type: Review

References (24)

1. Benson AB III, Pregler JP, Bean JA, Rademaker AW, Eshler B, Anderson K. Oncologists' reluctance to accrue patients onto clinical trials: an Illinois Cancer Center study. J Clin Oncol. 1991;9(11):2067-2075.
2. Coalition of Cancer Cooperative Groups. Cancer Clinical Trial Resources: Cancer Survivor Survey Results. http://www.cancertrialshelp.org/Icare-content/ icMainContent.aspx?intAppMode=19#destination-one. Accessed September 20, 2011.
3. Gross CP, Murthy V, Li Y, Kaluzny AD, Krumholz HM. Cancer trial enrollment after state-mandated reimbursement. J Natl Cancer Inst. 2004;96(14):1063-1069. (Pubitemid 39172407)
4. Health Policy, Patient and Practice Issues. Experts discuss the current state of cancer clinical trials. http://www.hemonctoday.com/article.aspx?rid= 64838. Accessed September 20, 2011.
5. Sateren W, Trimble E, Abrams J, et al. How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. J Clin Oncol. 2002;20(8):2109-2117. (Pubitemid 34408802)
6. O'Shaughnessy J, Osborne C, Pippen JE, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med. 2011;364(3):205-214.
7. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115-124. (Pubitemid 46089672)
8. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(22):3584-3590.
9. Blagoev KB, Wilkerson J, Stein WD, Motzer RJ, Bates SE, Fojo AT. Effect of sunitinib (SU) administration on post-treatment survival in patients with metastatic renal cell carcinoma (mRCC) treated on the upfront randomized phase III trial of sunitinib or interferon alfa (IFN). J Clin Oncol. 2011;29(suppl) Abstract 4634.
10. Clarke MJ, Mulligan EA, Grogan PT, et al. Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines. Mol Cancer Ther. 2009;8(2):407-414.
11. Näppä U, Lindqvist O, Rasmussen BH, Axelsson B. Palliative chemotherapy during the last month of life [published online ahead of print March 14, 2011]. Ann Oncol. 2011.
12. Fidias PM, Dakhil SR, Lyss AP, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. 2009;27(4):591-598.
13. Wilkerson J, Fojo T. Progression-free survival is simply a measure of a drug's effect while administered and is not a surrogate for overall survival. Cancer J. 2009;15(5):379-385.
14. O'Shaughnessy J, Schwartzberg LS, Danso MA, et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). Program and abstracts of the American Society of Clinical Oncology; June 3-7, 2011; Chicago, Illinois. J Clin Oncol. 2011;29(suppl). Abstract 1007.
15. Ozols RF, Behrens BC, Ostchega Y, Young RC. High dose cisplatin and high dose carboplatin in refractory ovarian cancer. Cancer Treat Rev. 1985;12(suppl A):59-65. (Pubitemid 16167901)
16. Levin L, Hryniuk WM. Dose intensity analysis of chemotherapy regimens in ovarian cancer. J Clin Oncol. 1987;5(5):756-767. (Pubitemid 17120253)
17. Ozols RF, Ostchega Y, Myers CE, Young RC. High-dose cisplatin in hypertonic saline in refractory ovarian cancer. J Clin Oncol. 1985;3(9):1246-1250. (Pubitemid 15226530)
18. Ozols RF, Ostchega Y, Curt G, Young RC. High-dose carboplatin in refractory ovarian cancer patients. J Clin Oncol. 1987;5(2):197-201. (Pubitemid 17021599)
19. Meng J, Dai B, Fang B, et al. Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. PLoS One. 2010;5(11):e14124.
20. Rinehart J, Adjei AA, Lorusso PM, et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol. 2004;22(22):4456-4462. (Pubitemid 41185111)
21. Lorusso PM, Adjei AA, Varterasian M, et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol. 2005;23(23):5281-5293. (Pubitemid 46206982)
22. Hainsworth JD, Cebotaru CL, Kanarev V, et al. A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens. J Thorac Oncol. 2010;5(10):1630- 1636.
23. Bennouna J, Lang I, Valladares-Ayerbes M, et al. A phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens [published online ahead of print February 2, 2010]. Invest New Drugs. 2010.
24. Haura EB, Ricart AD, Larson TG, et al. A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res. 2010;16(8):2450-2457.